Published in Front Endocrinol (Lausanne) on March 31, 2017
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med (2013) 8.89
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sci U S A (1990) 7.39
MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood (2006) 5.95
Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell (2007) 4.31
Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell (2007) 3.39
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl. Blood (1996) 3.14
Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature (1994) 3.13
Differential expression of novel potential regulators in hematopoietic stem cells. PLoS Genet (2005) 3.11
Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci U S A (1998) 2.79
Thrombocytopenia in c-mpl-deficient mice. Science (1994) 2.64
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood (2001) 2.52
Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (1994) 2.41
Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med (1998) 2.29
Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood (2004) 2.27
Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med (1997) 2.22
Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood (2001) 2.21
Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med (1996) 2.20
Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci U S A (1992) 2.17
Critical cytoplasmic domains of the common beta subunit of the human GM-CSF, IL-3 and IL-5 receptors for growth signal transduction and tyrosine phosphorylation. EMBO J (1992) 2.11
The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell (2001) 2.10
Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood (1996) 2.03
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domain. Proc Natl Acad Sci U S A (2001) 2.00
JAK/STAT signaling in hematological malignancies. Oncogene (2012) 1.96
Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell (1994) 1.93
A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell (1990) 1.89
YRRL motifs in the cytoplasmic domain of the thrombopoietin receptor regulate receptor internalization and degradation. Blood (2008) 1.86
cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature (1994) 1.85
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Mol Cell (2003) 1.84
Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol (2005) 1.83
Functional domains of the granulocyte colony-stimulating factor receptor. EMBO J (1991) 1.82
Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science (1997) 1.73
The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif. Mol Cell (2001) 1.72
Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci U S A (2004) 1.72
Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood (2008) 1.64
Structural basis of recognition of interferon-α receptor by tyrosine kinase 2. Nat Struct Mol Biol (2014) 1.64
Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A (1999) 1.61
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood (2012) 1.59
Activating mutations in human acute megakaryoblastic leukemia. Blood (2008) 1.56
The amino terminus of JAK3 is necessary and sufficient for binding to the common gamma chain and confers the ability to transmit interleukin 2-mediated signals. Proc Natl Acad Sci U S A (1997) 1.53
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood (2005) 1.50
Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood (2015) 1.41
Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem (2005) 1.41
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets. Blood (2010) 1.41
Dissecting the thrombopoietin receptor: functional elements of the Mpl cytoplasmic domain. Proc Natl Acad Sci U S A (1997) 1.39
Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes. Blood (2008) 1.39
The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony-stimulating factor receptor beta c chain. J Biol Chem (1995) 1.38
Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci U S A (1995) 1.34
Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood (1999) 1.34
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood (2015) 1.32
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica (2011) 1.25
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood (2002) 1.25
Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro. FEBS Lett (1995) 1.22
The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp Hematol (1995) 1.21
The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood (1995) 1.20
Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol (2008) 1.20
Specific contribution of Tyk2 JH regions to the binding and the expression of the interferon alpha/beta receptor component IFNAR1. J Biol Chem (1998) 1.19
Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood (2016) 1.18
Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem (1999) 1.18
Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood (1996) 1.12
Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood (2009) 1.12
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol (2007) 1.10
The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signaling but plays a structural role for receptor interaction and up-regulation of receptor surface expression. J Biol Chem (2005) 1.10
The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipper. J Biol Chem (2003) 1.08
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood (2009) 1.08
Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation. Proc Natl Acad Sci U S A (2014) 1.08
Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood (1999) 1.07
Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray. Exp Hematol (2008) 1.05
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets. Blood (1996) 1.05
N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit is essential for ligand binding and signal transduction. J Biol Chem (1995) 1.04
Molecular cloning and chromosomal localization of the human thrombopoietin gene. FEBS Lett (1994) 1.04
Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell (2015) 1.02
Phosphatidylinositol 3-kinase is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J Biol Chem (2001) 1.02
Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood (1995) 1.01
The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling. Nat Med (2014) 1.01
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discov (2016) 1.00
Tyrosine-599 of the c-Mpl receptor is required for Shc phosphorylation and the induction of cellular differentiation. EMBO J (1996) 1.00
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulation. FASEB J (2011) 1.00
Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica (2009) 0.99
The proline-rich motif (PRM): a novel feature of the cytokine/hematopoietin receptor superfamily. Lymphokine Cytokine Res (1993) 0.99
Tryptophan at the transmembrane-cytosolic junction modulates thrombopoietin receptor dimerization and activation. Proc Natl Acad Sci U S A (2013) 0.99
Defective response to thrombopoietin and impaired expression of c-mpl mRNA of bone marrow cells in congenital amegakaryocytic thrombocytopenia. Br J Haematol (1997) 0.98
Internalization of the thrombopoietin receptor is regulated by 2 cytoplasmic motifs. Blood (2003) 0.98
Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood (1998) 0.98
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
Thrombopoietin (TPO) induces tyrosine phosphorylation and activation of STAT5 and STAT3. FEBS Lett (1995) 0.97
Functional analysis of the cytoplasmic domain of the human Mpl receptor for tyrosine-phosphorylation of the signaling molecules, proliferation and differentiation. FEBS Lett (1996) 0.96
Orientation-specific signalling by thrombopoietin receptor dimers. EMBO J (2011) 0.95
Dimerization of the erythropoietin receptor transmembrane domain in micelles. J Mol Biol (2006) 0.94
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm. Blood (2014) 0.93
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. Cancer Cell (2016) 0.93
NMR structural studies of interactions of a small, nonpeptidyl Tpo mimic with the thrombopoietin receptor extracellular juxtamembrane and transmembrane domains. J Biol Chem (2007) 0.92
A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood (2004) 0.90
Interleukin-6 increases thrombopoietin production in human hepatoma cells HepG2 and Hep3B. J Interferon Cytokine Res (2000) 0.89